Physician profile
Scott K Schultz
NPI 1841458056
$19,847.24
in general payments reported to CMS, 2019-2025
28 companies · $8,821 in 2025
The $8,821 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $913 · 2021: $1,635 · 2022: $1,316 · 2023: $704 · 2024: $5,525 · 2025: $8,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $2,702 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,250.00 |
| Food and Beverage | $2,702.18 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $12,477.03 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Allergan, INC. | $1,539.03 | 2019-2022 | |
| Alcon Vision LLC | $972.67 | 2019-2025 | Clareon, Rocklatan, Centurion |
| Johnson & Johnson Surgical Vision, INC. | $834.36 | 2019-2024 | Tecnis Iol, Catalys System |
| Abbvie INC. | $690.55 | 2022-2025 | Durysta, Vuity, Lumigan |
| New World Medical,INC. | $602.29 | 2021-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $321.99 | 2019-2021 | |
| Harrow Eye, LLC | $319.95 | 2024 | Iheezo, Vevye |
| Sun Pharmaceutical Industries INC. | $271.11 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $268.60 | 2022-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $222.12 | 2019-2021 | |
| Glaukos Corporation | $208.21 | 2022-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Idosetr |
| Stryker Corporation | $197.49 | 2022-2025 | Mako |
| Bausch & Lomb Americas INC. | $140.64 | 2022-2025 | Miebo, Infuse |
| Kala Pharmaceuticals, INC. | $136.76 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $115.04 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $79.49 | 2024-2025 | Xdemvy |
| Omeros Corporation | $67.83 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $58.23 | 2019-2020 | |
| Staar Surgical Company | $58.09 | 2019 | |
| Edwards Lifesciences Corporation | $56.94 | 2023 | Pascal |
| Shire North American Group INC | $45.91 | 2019 | |
| Thea Pharma INC. | $45.73 | 2023-2024 | Iyuzeh |
| Biotissue Holdings INC. | $29.93 | 2022 | |
| Sight Sciences, INC. | $25.66 | 2020-2023 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $22.70 | 2022 | |
| Rayner Intraocular Lenses Limited | $19.49 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.